Clinical Study

Brain Shuttle (Bp42230) A Study To Test The Safety And Effect Of The Study Drug At Different Dose Levels, Determine How Well It Is Tolerated, And Measure How The Body Absorbs And Distributes The Study Drug

Posted Date: Dec 14, 2022

  • Investigator: Lawrence Goldstick
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

The Study Drug (R07121932) combines an antibody with a "brain shuttle" molecule, which delivers it to the brain. The purpose of this study is to test the safety of the study drug at different dose levels; determine how well it is tolerated by you and other participants; measure how the body absorbs, distributes, and gets ride of it (this is called "pharmacokinetics" [PK]); and find out what effects, good or bad, the Study Drug has on you.


Patients With Multiple Sclerosis Between The Ages Of 18 And 55 Who Have Not Had Ocrevus, Rituximab Or Kesimpta In The Last Year.


Ms, Multiple Sclerosis

For More Information:

Mikayla Hoeferlin

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.